

Contents

Powell, C.: Melvin Yahr (1917–2004). An appreciation	1
Kaufmann, H.: Melvin D. Yahr, 1917–2004. A personal recollection	5
 1. Pathology	
Hornykiewicz, O.: The discovery of dopamine deficiency in the parkinsonian brain	9
Heimer, G., Rivlin, M., Israel, Z., Bergman, H.: Synchronizing activity of basal ganglia and pathophysiology of Parkinson's disease	17
Wichmann, T., DeLong, M. R.: Basal ganglia discharge abnormalities in Parkinson's disease	21
Brown, P.: Bad oscillations in Parkinson's disease	27
McKeown, M. J., Palmer, S. J., Au, W.-L., McCaig, R. G., Saab, R., Abu-Gharbieh, R.: Cortical muscle coupling in Parkinson's disease (PD) bradykinesia	31
Burke, R. E.: GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons	41
Gherbassi, D., Simon, H. H.: The engrailed transcription factors and the mesencephalic dopaminergic neurons	47
Smits, S. M., Smidt, M. P.: The role of Pitx3 in survival of midbrain dopaminergic neurons	57
Ryu, S., Holzschuh, J., Mahler, J., Driever, W.: Genetic analysis of dopaminergic system development in zebrafish	61
Deutch, A. Y.: Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease	67
Fuxe, K., Manger, P., Genedani, S., Agnati, L.: The nigrostriatal DA pathway and Parkinson's disease	71
Parent, M., Parent, A.: Relationship between axonal collateralization and neuronal degeneration in basal ganglia.	85
Braak, H., Müller, C. M., Rüb, U., Ackermann, H., Bratzke, H., de Vos, R. A. I., Del Tredici, K.: Pathology associated with sporadic Parkinson's disease – where does it end?	89
Halliday, G. M., Del Tredici, K., Braak, H.: Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease	99
Giorgi, F. S., Bandettini di Poggio, A., Battaglia, G., Pellegrini, A., Murri, L., Ruggieri, S., Paparelli, A., Fornai, F.: A short overview on the role of α -synuclein and proteasome in experimental models of Parkinson's disease	105
Gispert-Sanchez, S., Auburger, G.: The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?	111

2. Iron and neuromelanin

- Double, K. L., Halliday, G. M.:** New face of neuromelanin 119
- Maruyama, W., Shamoto-Nagai, M., Akao, Y., Riederer, P., Naoi, M.:**
The effect of neuromelanin on the proteasome activity in human
dopaminergic SH-SY5Y cells 125
- Gerlach, M., Double, K. L., Youdim, M. B. H., Riederer, P.:**
Potential sources of increased iron in the substantia nigra
of parkinsonian patients 133
- Pandolfo, M.:** Iron and Friedreich ataxia. 143

3. Genetics

- Chade, A. R., Kasten, M., Tanner, C. M.:** Nongenetic causes
of Parkinson's disease 147
- Lannuzel, A., Höglinger, G. U., Champy, P., Michel, P. P.,
Hirsch, E. C., Ruberg, M.:** Is atypical parkinsonism in the Caribbean
caused by the consumption of Annonaceae? 153
- Mellick, G. D.:** CYP450, genetics and Parkinson's disease:
gene×environment interactions hold the key. 159
- Ravindranath, V., Kommaddi, R. P., Pai, H. V.:** Unique cytochromes
P450 in human brain: implication in disease pathogenesis 167
- Viaggi, C., Pardini, C., Vaglini, F., Corsini, G. U.:** Cytochrome P450
and Parkinson's disease: protective role of neuronal CYP 2E1
from MPTP toxicity. 173
- Miksys, S., Tyndale, R. F.:** Nicotine induces brain CYP enzymes:
relevance to Parkinson's disease 177
- Riess, O., Krüger, R., Hochstrasser, H., Soehn, A. S., Nuber, S.,
Franck, T., Berg, D.:** Genetic causes of Parkinson's disease:
extending the pathway 181
- Mizuno, Y., Hattori, N., Yoshino, H., Hatano, Y., Satoh, K.,
Tomiyaama, H., Li, Y.:** Progress in familial Parkinson's disease 191
- Hattori, N., Machida, Y., Sato, S., Noda, K., Iijima-Kitami, M.,
Kubo, S., Mizuno, Y.:** Molecular mechanisms of nigral neurodegeneration
in Park2 and regulation of parkin protein by other proteins 205
- Dawson, T. M.:** Parkin and defective ubiquitination in Parkinson's disease 209
- Heutink, P.:** PINK-1 and DJ-1 – new genes for autosomal recessive
Parkinson's disease 215
- Whaley, N. R., Uitti, R. J., Dickson, D. W., Farrer, M. J., Wszolek, Z. K.:**
Clinical and pathologic features of families with *LRRK2*-associated
Parkinson's disease 221
- Gasser, T.:** Molecular genetic findings in *LRRK2* American, Canadian
and German families 231

4. Imaging

- Lu, C.-S., Wu Chou, Y.-H., Weng, Y.-H., Chen, R.-S.:** Genetic and DAT
imaging studies of familial parkinsonism in a Taiwanese cohort 235
- Lok Au, W., Adams, J. R., Troiano, A., Stoessl, A. J.:**
Neuroimaging in Parkinson's disease 241
- Berg, D.:** Transcranial sonography in the early and differential diagnosis
of Parkinson's disease 249

5. Models

Hirsch, E. C.: How to judge animal models of Parkinson's disease in terms of neuroprotection	255
Falkenburger, B. H., Schulz, J. B.: Limitations of cellular models in Parkinson's disease research	261
Höglinger, G. U., Oertel, W. H., Hirsch, E. C.: The Rotenone model of Parkinsonism – the five years inspection	269
Schmidt, W. J., Alam, M.: Controversies on new animal models of Parkinson's disease Pro and Con: the rotenone model of Parkinson's disease (PD)	273
Kostrzewska, R. M., Kostrzewska, J. P., Brus, R., Kostrzewska, R. A., Nowak, P.: Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum.	277
Mochizuki, H., Yamada, M., Mizuno, Y.: α -Synuclein overexpression model	281
Németh, H., Toldi, J., Vécsei, L.: Kynurenes, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.	285

6. Clinical approaches

Goetz, C. G.: What's new? Clinical progression and staging of Parkinson's disease.	305
Wolters, E. Ch., Braak, H.: Parkinson's disease: premotor clinico-pathological correlations	309
Berendse, H. W., Ponsen, M. M.: Detection of preclinical Parkinson's disease along the olfactory tract.	321
Giladi, N., Balash, Y.: The clinical approach to gait disturbances in Parkinson's disease; maintaining independent mobility.	327
Bodis-Wollner, I., Jo, M.-Y.: Getting around and communicating with the environment: visual cognition and language in Parkinson's disease.	333
Goldstein, D. S.: Cardiovascular aspects of Parkinson disease.	339
Mathias, C. J.: Multiple system atrophy and autonomic failure.	343
Comella, C. L.: Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview	349
Arnulf, I.: Sleep and wakefulness disturbances in Parkinson's disease	357

7. Neuroinflammation

Burn, D. J.: Parkinson's disease dementia: what's in a Lewy body?	361
Qian, L., Hong, J.-S., Flood, P. M.: Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10	367
Sawada, M., Imamura, K., Nagatsu, T.: Role of cytokines in inflammatory process in Parkinson's disease.	373

8. Neurosurgery

Benabid, A. L., Chabardès, S., Seigneuret, E., Fraix, V., Krack, P., Pollak, P., Xia, R., Wallace, B., Sauter, F.: Surgical therapy for Parkinson's disease	383
Hamani, C., Neimat, J., Lozano, A. M.: Deep brain stimulation for the treatment of Parkinson's disease	393
Stefani, A., Fedele, E., Galati, S., Raiteri, M., Pepicelli, O., Brusa, L., Pierantozzi, M., Peppe, A., Pisani, A., Gattoni, G., Hainsworth, A. H., Bernardi, G., Stanzione, P., Mazzone, P.: Deep brain stimulation in Parkinson's disease patients: biochemical evidence	401

Agid, Y., Schüpbach, M., Gargiulo, M., Mallet, L., Houeto, J. L., Behar, C., Maltête, D., Mesnage, V., Welter, M. L.: Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so?	409
9. L-Dopa	
de la Fuente-Fernández, R., Lidstone, S., Stoessl, A. J.: Placebo effect and dopamine release.	415
Fahn, S.: A new look at levodopa based on the ELLDOPA study	419
Chouza, C., Buzó, R., Scaramelli, A., Romero, S., de Medina, O., Aljanati, R., Dieguez, E., Lisanti, N., Gomensoro, J.: Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations	427
10. Neuroprotection	
Uitti, R. J., Wszolek, Z. K.: Concerning neuroprotective therapy for Parkinson's disease.	433
Zigmond, M. J.: Triggering endogenous neuroprotective mechanisms in Parkinson's disease: studies with a cellular model	439
Weinstock, M., Luques, L., Bejar, C., Shoham, S.: Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression	443
Gal, S., Fridkin, M., Amit, T., Zheng, H., Youdim, M. B. H.: M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.	447
Weinreb, O., Amit, T., Bar-Am, O., Sagi, Y., Mandel, S., Youdim, M. B. H.: Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety	457
11. Other treatment strategies	
Schulz, J. B.: Anti-apoptotic gene therapy in Parkinson's disease	467
Kaufmann, H.: The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors	477
12. Dystonia	
Hallett, M.: Pathophysiology of dystonia	485
Bressman, S.: Genetics of dystonia	489
Index	497

Listed in Current Contents/Life Sciences

Parkinson's Disease and Related Disorders

Riederer, P.; Reichmann, H.; Youdim, M.B.H.; Gerlach, M.
(Eds.)

2006, X, 506 p. 75 illus., Hardcover

ISBN: 978-3-211-28927-3